- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00834366
A Study to Compare the Relative Bioavailability of Two 200 Mg Tramadol Hydrochloride Tablet Products Under Fasting Conditions
April 25, 2012 updated by: Labopharm Inc.
To determine whether the test product, Labopharm Tramadol HCl Once-A-Day (OAD) 200 mg film-coated tablets, and the reference product, Labopharm Tramadol HCl OAD 200 mg uncoated tablets, are bioequivalent.
Study Overview
Study Type
Interventional
Enrollment (Actual)
26
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy male and female subjects 18 to 55 years of age (inclusive).
- Body mass within 10% of the ideal mass in relation to height and age, according to the Body Mass Index (BMI).
- Body mass not less than 60 kg.
- Findings within the range of clinical acceptability in medical history and physical examination, and laboratory results within the "normal ranges" for the relevant laboratory tests (unless the investigator considered the deviation to be irrelevant for the purpose of the study).
- Normal electrocardiogram (ECG) and vital signs, or abnormalities which the investigator did not consider a disqualification for participation in the study.
- Willingness to undergo a pre-study physical examination and pre- and post-study laboratory investigations.
- Ability to comprehend and willingness to sign both statements of informed consent (for screening and phase-related procedures).
- Non-smoker or past smoker who stopped smoking at least 3 months before entering the study.
For females, the following conditions were to be met:
- had been postmenopausal for at least 2 years, or
- had been surgically sterilized, or
was of childbearing potential, and all of the following conditions were met:
- had a normal menstrual flow within 1 month before study entry, and
- had negative serum pregnancy test at screening. If this test was positive, the subject was to have been excluded from the study before receiving study medication. In the rare circumstance that a pregnancy was discovered after the subjects received study drug, then every attempt must be made to follow such subjects to term, and
- must agree to use an accepted method of contraception (i.e., spermicide and barrier methods or spermicide and Intrauterine Device (IUD)). The subject had to agree to continue with the same method throughout the study. Hormonal contraceptives will not be allowed.
Exclusion Criteria:
- Evidence of psychiatric disorder, antagonistic personality, poor motivation, emotional or intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with protocol requirements.
- History of, or current compulsive alcohol abuse (>10 drinks weekly), or regular exposure to other substances of abuse.
- Use of any medication, prescribed or over-the-counter, within 2 weeks prior to the first administration of study medication except if this would not have affected the outcome of the study in the opinion of the clinical investigator. Use of hormonal contraceptive agents by females were not allowed.
- Participation in another study with an experimental drug within 8 weeks before the first administration of study medication.
- Treatment within the previous 3 months with any drug with a well-defined potential for adversely affecting a major organ or system with evidence to this effect.
- A major illness during the 3 months before commencement of the screening period.
- History of hypersensitivity to the study drug or any related drugs.
- History of bronchial asthma.
- History of epilepsy.
- Relevant history or laboratory or clinical findings indicative of acute or chronic disease, likely to influence study outcome.
- Donation or loss of blood equal to or exceeding 500 mL during the 8 weeks before the first administration of study medication.
- Diagnosis of hypotension made during the screening period.
- Diagnosis of hypertension made during the screening period or current diagnosis of hypertension.
- Resting pulse of >100 beats per minute or <45 beats per minute during the screening period, either supine or standing.
- Positive testing for hepatitis B antigen.
- Significant liver disease, defined as active hepatitis or elevated liver enzymes (e.g., AST (aspartate aminotransferase), Alanine transaminase (ALT)) >2 times the upper boundary of the normal range.
- Positive urine screen for drugs of abuse.
- Positive urine screen for tobacco use (SureStepTM Smoke Check Tests and One-Step Cotinine (COT) Tests).
- A serum pregnancy test (beta-hCG) either positive or not performed or lactation.
- History of marijuana, barbiturate, amphetamine or narcotic abuse within 12 months prior to study start.
- Participation in a tramadol study within the previous 12 months.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Tramadol HCl 200 mg Film-coated Tablets
Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet based on randomization schedule.
|
Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet or Tramadol HCl 200 mg Uncoated Tablets based on randomization schedule.
|
EXPERIMENTAL: Tramadol HCl 200 mg Uncoated Tablets
Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Uncoated Tablet based on randomization schedule.
|
Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet or Tramadol HCl 200 mg Uncoated Tablets based on randomization schedule.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax
Time Frame: 48 hours
|
Maximum plasma concentration
|
48 hours
|
AUC(0-t)
Time Frame: 48 hours
|
Area under plasma concentration versus time curve to the last measurable concentration.
Unit is ng.h/mL.
h=hours.
|
48 hours
|
AUC(0-Inf)
Time Frame: 48 hours
|
Area under plasma concentration versus time curve extrapolated to infinity.
Unit is ng.h/mL.
h=hour.
|
48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
t1/2
Time Frame: 48 hours
|
Apparent terminal elimination half-life
|
48 hours
|
Tmax
Time Frame: 48 hours
|
Time to the maximum concentration
|
48 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2005
Primary Completion (ACTUAL)
March 1, 2005
Study Completion (ACTUAL)
March 1, 2005
Study Registration Dates
First Submitted
January 30, 2009
First Submitted That Met QC Criteria
February 2, 2009
First Posted (ESTIMATE)
February 3, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
April 30, 2012
Last Update Submitted That Met QC Criteria
April 25, 2012
Last Verified
April 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MDT1-013
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Tramadol HCl
-
Janssen Korea, Ltd., KoreaCompleted
-
Labopharm Inc.Completed
-
Hadassah Medical OrganizationGrumentalCompletedRenal CalculusIsrael
-
Janssen Korea, Ltd., KoreaCompleted
-
Bausch Health Americas, Inc.Completed
-
Labopharm Inc.CompletedHealthy Subjects | Pharmacokinetics | Bioavailability
-
Bausch Health Americas, Inc.Completed
-
Janssen Scientific Affairs, LLCBausch Health Americas, Inc.; Cipher Pharmaceuticals Inc.CompletedHealthyUnited States